Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease

Lori Zacharoff, Ivan Tkac, Qingfeng Song, Chuanning Tang, Patrick J Bolan, Silvia Mangia, Pierre-Gilles Henry, Tongbin Li, Janet M Dubinsky

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

To improve the ability to move from preclinical trials in mouse models of Huntington's disease (HD) to clinical trials in humans, biomarkers are needed that can track similar aspects of disease progression across species. Brain metabolites, detectable by magnetic resonance spectroscopy (MRS), have been suggested as potential biomarkers in HD. In this study, the R6/2 transgenic mouse model of HD was used to investigate the relative sensitivity of the metabolite profiling and the brain volumetry to anticipate the disease progression. Magnetic resonance imaging (MRI) and 1H MRS data were acquired at 9.4 T from the R6/2 mice and wild-type littermates at 4, 8, 12, and 15 weeks. Brain shrinkage was detectable in striatum, cortex, thalamus, and hypothalamus by 12 weeks. Metabolite changes in cortex paralleled and sometimes preceded those in striatum. The entire set of metabolite changes was compressed into principal components (PCs) using Partial Least Squares-Discriminant Analysis (PLS-DA) to increase the sensitivity for monitoring disease progression. In comparing the efficacy of volume and metabolite measurements, the cortical PC1 emerged as the most sensitive single biomarker, distinguishing R6/2 mice from littermates at all time points. Thus, neurochemical changes precede volume shrinkage and become potential biomarkers for HD mouse models.

Original languageEnglish (US)
Pages (from-to)502-514
Number of pages13
JournalJournal of Cerebral Blood Flow and Metabolism
Volume32
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Huntington Disease
Biomarkers
Disease Progression
Brain
Magnetic Resonance Spectroscopy
Aptitude
Discriminant Analysis
Least-Squares Analysis
Thalamus
Transgenic Mice
Hypothalamus
Magnetic Resonance Imaging
Clinical Trials

Keywords

  • biomarker
  • in-vivo H MR spectroscopy
  • metabolite profiles
  • metabolomics
  • principal-least square discriminant analysis

Cite this

Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease. / Zacharoff, Lori; Tkac, Ivan; Song, Qingfeng; Tang, Chuanning; Bolan, Patrick J; Mangia, Silvia; Henry, Pierre-Gilles; Li, Tongbin; Dubinsky, Janet M.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 32, No. 3, 01.03.2012, p. 502-514.

Research output: Contribution to journalArticle

@article{f52888e3ba87437fbb29fd10e9d87262,
title = "Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease",
abstract = "To improve the ability to move from preclinical trials in mouse models of Huntington's disease (HD) to clinical trials in humans, biomarkers are needed that can track similar aspects of disease progression across species. Brain metabolites, detectable by magnetic resonance spectroscopy (MRS), have been suggested as potential biomarkers in HD. In this study, the R6/2 transgenic mouse model of HD was used to investigate the relative sensitivity of the metabolite profiling and the brain volumetry to anticipate the disease progression. Magnetic resonance imaging (MRI) and 1H MRS data were acquired at 9.4 T from the R6/2 mice and wild-type littermates at 4, 8, 12, and 15 weeks. Brain shrinkage was detectable in striatum, cortex, thalamus, and hypothalamus by 12 weeks. Metabolite changes in cortex paralleled and sometimes preceded those in striatum. The entire set of metabolite changes was compressed into principal components (PCs) using Partial Least Squares-Discriminant Analysis (PLS-DA) to increase the sensitivity for monitoring disease progression. In comparing the efficacy of volume and metabolite measurements, the cortical PC1 emerged as the most sensitive single biomarker, distinguishing R6/2 mice from littermates at all time points. Thus, neurochemical changes precede volume shrinkage and become potential biomarkers for HD mouse models.",
keywords = "biomarker, in-vivo H MR spectroscopy, metabolite profiles, metabolomics, principal-least square discriminant analysis",
author = "Lori Zacharoff and Ivan Tkac and Qingfeng Song and Chuanning Tang and Bolan, {Patrick J} and Silvia Mangia and Pierre-Gilles Henry and Tongbin Li and Dubinsky, {Janet M}",
year = "2012",
month = "3",
day = "1",
doi = "10.1038/jcbfm.2011.157",
language = "English (US)",
volume = "32",
pages = "502--514",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease

AU - Zacharoff, Lori

AU - Tkac, Ivan

AU - Song, Qingfeng

AU - Tang, Chuanning

AU - Bolan, Patrick J

AU - Mangia, Silvia

AU - Henry, Pierre-Gilles

AU - Li, Tongbin

AU - Dubinsky, Janet M

PY - 2012/3/1

Y1 - 2012/3/1

N2 - To improve the ability to move from preclinical trials in mouse models of Huntington's disease (HD) to clinical trials in humans, biomarkers are needed that can track similar aspects of disease progression across species. Brain metabolites, detectable by magnetic resonance spectroscopy (MRS), have been suggested as potential biomarkers in HD. In this study, the R6/2 transgenic mouse model of HD was used to investigate the relative sensitivity of the metabolite profiling and the brain volumetry to anticipate the disease progression. Magnetic resonance imaging (MRI) and 1H MRS data were acquired at 9.4 T from the R6/2 mice and wild-type littermates at 4, 8, 12, and 15 weeks. Brain shrinkage was detectable in striatum, cortex, thalamus, and hypothalamus by 12 weeks. Metabolite changes in cortex paralleled and sometimes preceded those in striatum. The entire set of metabolite changes was compressed into principal components (PCs) using Partial Least Squares-Discriminant Analysis (PLS-DA) to increase the sensitivity for monitoring disease progression. In comparing the efficacy of volume and metabolite measurements, the cortical PC1 emerged as the most sensitive single biomarker, distinguishing R6/2 mice from littermates at all time points. Thus, neurochemical changes precede volume shrinkage and become potential biomarkers for HD mouse models.

AB - To improve the ability to move from preclinical trials in mouse models of Huntington's disease (HD) to clinical trials in humans, biomarkers are needed that can track similar aspects of disease progression across species. Brain metabolites, detectable by magnetic resonance spectroscopy (MRS), have been suggested as potential biomarkers in HD. In this study, the R6/2 transgenic mouse model of HD was used to investigate the relative sensitivity of the metabolite profiling and the brain volumetry to anticipate the disease progression. Magnetic resonance imaging (MRI) and 1H MRS data were acquired at 9.4 T from the R6/2 mice and wild-type littermates at 4, 8, 12, and 15 weeks. Brain shrinkage was detectable in striatum, cortex, thalamus, and hypothalamus by 12 weeks. Metabolite changes in cortex paralleled and sometimes preceded those in striatum. The entire set of metabolite changes was compressed into principal components (PCs) using Partial Least Squares-Discriminant Analysis (PLS-DA) to increase the sensitivity for monitoring disease progression. In comparing the efficacy of volume and metabolite measurements, the cortical PC1 emerged as the most sensitive single biomarker, distinguishing R6/2 mice from littermates at all time points. Thus, neurochemical changes precede volume shrinkage and become potential biomarkers for HD mouse models.

KW - biomarker

KW - in-vivo H MR spectroscopy

KW - metabolite profiles

KW - metabolomics

KW - principal-least square discriminant analysis

UR - http://www.scopus.com/inward/record.url?scp=84857791811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857791811&partnerID=8YFLogxK

U2 - 10.1038/jcbfm.2011.157

DO - 10.1038/jcbfm.2011.157

M3 - Article

C2 - 22044866

AN - SCOPUS:84857791811

VL - 32

SP - 502

EP - 514

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 3

ER -